Prolonged Beneficial Effects of Dobutamine in Refractory Heart Failure -- Case Histories

Puram, Brahmaji; Margolis, Jack; Puram, Vijayalakshmi
August 1987
Angiology;Aug1987, Vol. 38 Issue 8, p631
Academic Journal
Two patients with refractory congestive heart failure were treated with dobutamine for forty-eight to seventy-two hours with close monitoring of weight and symptomatology. After two to four cycles of dobutamine treatment, 1 patient showed sustained hemodynamic benefit after six months, whereas the second patient had partial improvement. At the end of a one-year follow-up, both had sustained improvement in effort tolerance, documented by a stress test. The quality of life has markedly improved, and they have not required further hospital care.


Related Articles

  • Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Bolano, E.; Täng, M. Scharin; Hjalmarson, Å.; Waagstein, F.; Andersson, B. // Heart;Jun2003, Vol. 89 Issue 6, p621 

    Objective: To determine whether patients with congestive heart failure on different β adrenoreceptor blocking drugs have similar haemodynamic responses to dobutamine. Design: Single centre, single blind, randomised, two period crossover study comparing carvedilol with metoprolol CR/XL....

  • Arrhythmias Associated with Intermittent Outpatient Dobutamine Infusion. David, Shukri; Zaks, Jeffrey M. // Angiology;Feb1986, Vol. 37 Issue 2, p86 

    The use of intermittent outpatient dobutamine infusion has recently been studied as an alternative therapy modality for patients with refractory congestive heart failure. We studied the arrhythmogenic effects of intermittent outpatient dobutamine infusion in two patients with NYHA class IV heart...

  • Candesartan in CHF Patients with Normal LV Function. Barry, Henry // American Family Physician;1/1/2004, Vol. 69 Issue 1, p164 

    Examines the effects of candesartan in patients with congestive heart failure and preserved left-ventricular ejection fraction. Clinical questions on the case; Clinical setting; Discussion on the results of the study.

  • Candesartan Plus ACE Inhibitor for CHF. Barry, Henry // American Family Physician;1/1/2004, Vol. 69 Issue 1, p164 

    Studies the effects of candesartan in patients with congestive heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors. Clinical setting of the study; Study design; Discussion on the result of the study.

  • Enhancement of Phentolamine by Nitrates in Patients with Congestive Heart Failure. Gould, Lawrence; Reddy, C. V. R.; Zen, Bujung; Singh, B. K. // Angiology;Sep1981, Vol. 32 Issue 9, p595 

    Phentolamine dilates the resistance bed and to a lesser degree the capacitance bed, while the nitrates have the opposite action. Therefore, in 7 patients with congestive heart failure due to congestive cardiomyopathy, hemodynamic measurements were made using a Swan Ganz thermodilution catheter...

  • LETTERS AND CORRECTIONS.  // Annals of Internal Medicine;Dec86, Vol. 105 Issue 6, p965 

    Presents letters and corrections from the readers of the 'Annals of Internal Medicine.' Hemoperfusion for N-Acetylprocainamide intoxication; Complications of dobutamine in patients with severe congestive heart failure; Extracorporeal shock-wave lithotripsy and prophylaxis for endocarditis.

  • Congestive heart failure with a noncoronary cause. Manzoor, Naila // Cortlandt Forum;11/25/99, Vol. 12 Issue 11, p248 

    Examines the case of a 66-year-old man with congestive heart failure with a non-coronary cause. Medical history; Physical examination findings; Diagnosis; Treatment.

  • Congestive Heart Failure. Braunwald, Eugene; Chidsey, Charles A.; Pool, Peter E.; Sonnenblick, Edmund H.; Ross Jr., John; Mason, Dean T.; Spann, James F.; Covell, James W. // Annals of Internal Medicine;Apr66, Vol. 64 Issue 4, p904 

    Discusses biochemical and physiological considerations in the diagnosis of congestive heart failure. Cardiac metabolism; Oxidative phosphorylation and mitochondria; Stores of high-energy phosphate in acute and chronic failure.

  • Lifetime Risk of Developing Congestive Heart Failure. Carter, Chuck // American Family Physician;3/15/2003, Vol. 67 Issue 6, p1339 

    Discusses the study 'Lifetime Risk for Developing Congestive Heart Failure. The Framingham Heart Study,' by D.M. Lloyd-Jones et al., from the December 10, 2002 issue of 'Circulation.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics